Safety and Efficacy Study of Salvage Chemotherapy (R-ESHAP) to Treat Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00367497 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped The stopping rule was applied because of low response rates.

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin

Sponsor

Keio University